Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CER-081
- Development stage
- Preclinical
- Lead developer
- Cerecin
- Modality
- Small Molecules
- Administration
- Parenteral
01
Overview
CER-081 is a preclinical-stage small molecule ketone precursor being developed by Cerecin (formerly Accera) for the treatment of acute neurological conditions, including traumatic brain injury (TBI) and stroke. Administered parenterally, CER-081 is designed to rapidly provide ketone bodies as an alternative metabolic substrate to the brain during periods of metabolic crisis or glucose hypometabolism following acute injury. This neurometabolic approach aims to support brain energy metabolism and mitigate secondary injury in settings where rapid metabolic support is required, offering a potential therapeutic option for patients in emergency neurological care.
Beyond the preview
Go deeper on CER-081.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CER-081.